71 results
Page 2 of 4
8-K
EX-99.1
fyb8bq
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
vbjb05pj ce3zy54l
30 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
jamddvaemh86 jym5o
28 Mar 22
Soleno Therapeutics Announces Proposed Underwritten Public Offering
4:59pm
424B5
szfut
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
sjphxc5l qmmg0aahm
24 Jan 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:06am
8-K
EX-99.1
x97zg4od f8qdmm
10 Nov 21
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:16pm
424B5
cxpcq3xrlyu ad2sv4
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
p7dt rkxu21x1
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
EX-99.2
nc46nkeupifnzq2e
15 Apr 21
Other Events
12:00am
8-K
EX-99.1
sttmel11vp030ry0ue
8 Mar 21
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
4:01pm
8-K
EX-99.1
r2xs3l6vdhqpjfbe8
3 Mar 21
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year
4:01pm
8-K
EX-99.1
k6fkqs4ia8jgplkiub
11 Dec 20
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:31am
8-K
EX-99.1
9aadizlynx68qi 9f83
10 Nov 20
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
4:22pm
8-K
EX-99.1
b1dydz2az9149xljj
10 Aug 20
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results
4:09pm
424B5
8xna9
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
bx62x
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.2
uzdfz
8 Jun 20
Regulation FD Disclosure
5:04pm
8-K
EX-99.1
7nvncms njzi
12 May 20
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
4:05pm